Neuroprotection with gluthatione in brain ischemia reperfusion injury

Abstract

Up to 23% of strokes are caused by transient ischemic attack (TIA). Oxidative stress aggravates brain injury following cerebral ischemia. The treatment of anti-oxidant, edaravone is now the standard clinical therapy for only the acute phase of TIA, particularly in Japan. However, edaravone has side effects including acute renal failure and its therapeutic time window is narrow. Thus, safe and prolonged anti-oxidative therapy in the sub-acute phase is required to prevent progressive brain damage after TIA. The glutathione (GSH) system plays a pivotal role in combating oxidative stress. Here, we introduce therapeutic candidates, GSH which elucidates an elevation anti-oxidative system in the brain and inhibits the post-ischemia neuronal damages.